Anixa Biosciences Inc.
Organization details
- Legal name
- Anixa Biosciences Inc.
- Former names
- ITUS Corp Copytele Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Jose
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- October
- Ticker symbol
- ANIX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000715446
- EIN
- 11-2622630
Board of directors
-
Amit Kumar · Director · Chief Executive OfficerSince 2023
-
Arnold M. Baskies · DirectorSince 2023
-
Emily Gottschalk · DirectorSince 2023
-
Lewis H. Titterton Jr. · DirectorSince 2023
Chief executives
Director election results
Annual meeting of March 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.6%
-
79.4%
-
81.3%
-
97.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $521,772
- 21 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $3.17 | $15,850 |
| Oct 23, 2026 | Lewis H. Titterton Jr. Director | Open-market purchase | +8,000 | $2.98 | $23,840 |
| Oct 22, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +8,000 | $2.72 | $21,760 |
| Sep 30, 2026 | Catelani Michael Officer (President, COO, & CFO) | Open-market purchase | +5,500 | $2.84 | $15,620 |
| Sep 24, 2026 | Arnold M. Baskies Director | Open-market purchase | +5,000 | $2.76 | $13,800 |
| Sep 24, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +7,000 | $2.78 | $19,460 |
| Sep 23, 2026 | Lewis H. Titterton Jr. Director | Open-market purchase | +49,036 | $2.69 | $131,907 |
| Sep 10, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $2.76 | $13,800 |
| Sep 10, 2026 | Lewis H. Titterton Jr. Director | Open-market purchase | +10,000 | $2.73 | $27,300 |
| Sep 10, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +3,000 | $2.75 | $8,250 |
| Jul 31, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $3.47 | $17,350 |
| Jul 27, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +3,188 | $3.37 | $10,744 |
| Jul 27, 2026 | Amit Kumar Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $3.44 | $17,200 |
| Jul 27, 2026 | Arnold M. Baskies Director | Option exercise | +6,000 | $3.13 | $18,780 |
| Jul 27, 2026 | Arnold M. Baskies Director | Shares withheld for tax | −5,428 | $3.46 | $18,781 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Anixa Biosciences Inc.
Who is the CEO of Anixa Biosciences Inc.?
Amit Kumar is Anixa Biosciences Inc.'s Chief Executive Officer.
How many directors are on Anixa Biosciences Inc.'s board?
Anixa Biosciences Inc.'s board has 4 directors: Amit Kumar, Arnold M. Baskies, Emily Gottschalk and Lewis H. Titterton Jr.
Are Anixa Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, Anixa Biosciences Inc. insiders bought $521,772 of shares in 21 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="anixa-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.